Clinical detection and categorization of uncommon and concomitant mutations involving BRAF

Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool

(2015) Jamal Carter et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers

(2015) Lisa Haley et al.   MODERN PATHOLOGY

Clinical Validation of KRAS, BRAF, and EGFR Mutation Detection Using Next-Generation Sequencing

(2014) Ming-Tseh Lin et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

The role of systemic therapies in the management of melanoma brain metastases

(2014) Megan Lyle et al.   CURRENT OPINION IN ONCOLOGY

The role of MEK inhibitors in the treatment of metastatic melanoma

(2014) Antonio M. Grimaldi et al.   CURRENT OPINION IN ONCOLOGY

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

(2014) Grant A McArthur et al.   LANCET ONCOLOGY

BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib

(2014) Sara D. Robinson et al.   LUNG CANCER

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma

(2014) Samantha E. Bowyer et al.   MELANOMA RESEARCH

Tumor Cellularity as a Quality Assurance Measure for Accurate Clinical Detection of BRAF Mutations in Melanoma

(2014) Jonathan C. Dudley et al.   Molecular Diagnosis & Therapy

Mutationally Activated PIK3CAH1047R Cooperates with BRAFV600E to Promote Lung Cancer Progression

(2013) C. L. Trejo et al.   CANCER RESEARCH

Dramatic Response Induced by Vemurafenib in aBRAFV600E-Mutated Lung Adenocarcinoma

(2013) Solange Peters et al.   JOURNAL OF CLINICAL ONCOLOGY

Major Clinical Response to a BRAF Inhibitor in a Patient With a BRAF L597R–Mutated Melanoma

(2013) Philippe Bahadoran et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer

(2013) Charles M. Rudin et al.   Journal of Thoracic Oncology

BRAF inhibitor activity in V600R metastatic melanoma

(2012) Oliver Klein et al.   EUROPEAN JOURNAL OF CANCER

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

(2012) Kevin B. Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib

(2012) Oliver Gautschi et al.   Journal of Thoracic Oncology

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET ONCOLOGY

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib

(2012) B. Sen et al.   Science Translational Medicine

BRAF L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

(2012) Kimberly Brown Dahlman et al.   Cancer Discovery

Δ-PCR, A Simple Method to Detect Translocations and Insertion/Deletion Mutations

(2011) Ming-Tseh Lin et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma-Rationale for Comprehensive Mutation Profiling

(2011) J. E. Chaft et al.   MOLECULAR CANCER THERAPEUTICS

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung

(2010) Donatella Malanga et al.   CELL CYCLE

Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma

(2009) Libero Santarpia et al.   HUMAN PATHOLOGY

Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias

(2008) M S Kim et al.   BRITISH JOURNAL OF CANCER

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

(2008) K S M Smalley et al.   ONCOGENE

AKT1 E17K in human solid tumours

(2008) F E Bleeker et al.   ONCOGENE

Comparative lesion sequencing provides insights into tumor evolution

(2008) S. Jones et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA